About
Personalized Immuno-oncology Treatment
ImmuniQ has developed a method for quantifing the actual and functional tumor response to immunotherapy drugs. The company’s immune checkpoint artificial reporter (IcAR) technology is able to quantify binding and shows the actual surface activity of the patient’s cancer cells, enabling more effective treatment for each patient.
Identity
| Name | ImmuniQ |
|---|---|
| Slug | immuniq |
| Type / kind | startup |
| Source _id | dHHZIvNuEMkdNT9n80DQa7MUR3BR6FJZqkalvbJ6uqsJ9yDJ9sEX7Y |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Web & social
| Website | https://www.immuniq.tech/ |
|---|
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
pharmaceuticalsdrug-discoveryimmunologycancer
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}